基于细粒度图像识别的生成对抗网络用于预测渐进性轻度认知障碍的进展
Changsong Shen1,2, Fangxiang Wu1,3, Bo Liao4,5
1School of Mathematics and Statistics, Hainan Normal University, Haikou, 571158, China.
Interdisciplinary sciences, computational life sciences
|January 13, 2026
概括
这项研究引入了FGGAN,一种用于合成神经成像数据的新方法,以改善进展性轻度认知障碍 (pMCI) 的早期识别,这是阿尔茨海默病 (AD) 的前体. 通过生成高质量的多式模式脑图像,FGGAN提高了预测准确度.
科学领域:
- 神经成像是一种神经成像.
- 人工智能的人工智能
- 神经学 神经学
背景情况:
- 渐进性轻度认知障碍 (pMCI) 可以推进到阿尔茨海默病 (AD),使得早期识别对及时干预至关重要.
- 目前使用多模式神经成像数据 (MRI,PET) 进行pMCI预测的方法受到数据稀缺和低于最佳的跨模式合成的限制.
- 现有的生成对抗网络 (GAN) 通常无法在合成的神经图像中捕获本地细节,从而影响预测性能.
研究的目的:
- 开发一种新的生成对抗网络 (FGGAN),用于高质量的跨模态神经图像合成.
- 为了提高使用融合多模式神经影像特征的渐进轻度认知障碍 (pMCI) 的预测准确度.
- 解决现有的GAN在获取本地信息方面的局限性,以改善图像合成.
主要方法:
- 提出了一个细粒度生成对抗网络 (FGGAN),包括GAN,特征深度提取 (FDE) 模块和分类器.
- 在GAN合成缺失的神经成像模式使用本地和全球线索,提取多式联络特征表示.
- 该FDE模块改进了语义特征,以改善分类器的适应性,从而可以从合并的多式联络数据中预测pMCI进展.
主要成果:
- 与现有方法相比,FGGAN在合成高质量的交叉模式神经图像方面表现出卓越的表现.
- 拟议的方法在分类渐进性轻度认知障碍 (pMCI) 进展方面取得了更高的准确性.
- 对阿尔茨海默病神经成像计划 (ADNI) 数据集的验证证实了FGGAN的有效性.
结论:
- FGGAN有效地合成了多模式神经成像数据,克服了以前方法的局限性.
- 增强的图像合成质量直接有助于改善pMCI进展的预测.
- 这种方法对早期识别患有阿尔茨海默病风险的个体具有重要的临床价值.
相关概念视频
Prosopagnosia
693
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
693
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


